Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Rosell, Rafael ^a,b   Perez Roca, Laia ^a   Sanchez, Jose Javier ^c   Cobo, Manuel ^d   Moran, Teresa ^a   Chaib, Imane ^a   Provencio, Mariano ^e   Domine, Manuel ^f   Sala, Maria Angeles ^g   Jimenez, Ulpiano ^h   Diz, Pilar ⁱ   Barneto, Isidoro ^j   Macias, Jose Antonio ^k   de las Peñas, Ramon ^l   Catot, Silvia ^m   Isla, Dolores ⁿ   Sanchez, Jose Miguel ^o,u   Ibeas, Rafael ^p   Lopez Vivanco, Guillermo ^q   Oramas, Juana ^r   Mendez, Pedro ^a   Reguart, Noemi ^s   Blanco, Remei ^t   Taron, Miquel ^a,b   more..

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d Hospital Clinico Carlos Haya   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^f Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^g HOSPITAL DE BASURTO   (Spain)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁱ HOSPITAL DE LEÓN   (Spain)

^j HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^k HOSPITAL MORALES MESEGUER   (Spain)

^l HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

^m Althaia   (Spain)

ⁿ HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^o HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^p Hospital Municipal de Badalona   (Spain)

^q HOSPITAL DE CRUCES   (Spain)

^r HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^s HOSPITAL CLÍNIC   (Spain)

^t HOSPITAL DE TERRASSA   (Spain)

^u HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CARRIER PROTEIN; CISPLATIN; DEOXYCYTIDINE; DOCETAXEL; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; FAM175A PROTEIN, HUMAN; GEMCITABINE; MESSENGER RNA; NUCLEAR PROTEIN; RAP80 PROTEIN, HUMAN; RNA; TAXOID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CISPLATIN; DEOXYCYTIDINE; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PHARMACOGENETICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 67649431893     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005133     Document Type: Article

References (36)

1. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, et al.(2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016-3024.
2. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, et al.(2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551.
3. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, et al.(2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25: 2747-2754.
4. Guha U, Chaerkady R, Marimuthu A, Patterson AS, Kashyap MK, et al.(2008) Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A 105: 14112-14117.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al.(2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al.(2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
7. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al.(2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
8. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, et al.(2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26: 2442-2449.
9. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, et al.(2005) Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11: 5878-5885.
10. Costa DB, Kobayashi S, Tenen DG, Huberman MS, (2007) Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58: 95-103.
11. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, et al.(2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-865.
12. Lafarge S, Sylvain V, Ferrara M, Bignon YJ, (2001) Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20: 6597-6606.
13. Husain A, He G, Venkatraman ES, Spriggs DR, (1998) BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58: 1120-1123.
14. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK, (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275: 23899-23903.
15. Abbott DW, Thompson ME, Robinson-Benion C, Tomlinson G, Jensen RA, et al.(1999) BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 274: 18808-18812.
16. Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, et al.(2001) BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 20: 6123-6131.
17. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, et al.(2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63: 6221-6228.
18. Chabalier C, Lamare C, Racca C, Privat M, Valette A, et al.(2006) BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5: 1001-1007.
19. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, et al.(2007) BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy. Clin Cancer Res 13: 7413-7420.
20. Wang L, Wei J, Qian X, Yin H, Zhao Y, et al.(2008) ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 8: 97.
21. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, et al.(2004) BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13: 2443-2449.
22. Harper JW, Elledge SJ, (2007) The DNA damage response: ten years after. Mol Cell 28: 739-745.
23. Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, et al.(2007) Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 316: 1194-1198.
24. Sobhian B, Shao G, Lilli DR, Culhane AC, Moreau LA, et al.(2007) RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 316: 1198-1202.
25. Kim H, Chen J, Yu X, (2007) Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 316: 1202-1205.
26. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, et al.(2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20: 1496-1510.
27. Wang B, Elledge SJ, (2007) Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci U S A 104: 20759-20763.
28. Yan J, Kim YS, Yang XP, Li LP, Liao G, et al.(2007) The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response. Cancer Res 67: 6647-6656.
29. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al.(2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98.
30. Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, et al.(2007) Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 67: 8065-8080.
31. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, et al.(2007) BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer. PLoS ONE 2: e1129.
32. Ayoub N, Jeyasekharan AD, Bernal JA, Venkitaraman AR, (2008) HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response. Nature 453: 682-686.
33. P Oc, Rusch V, Talbot SG, Sarkaria I, Viale A, et al.(2004) Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin Cancer Res 10: 5792-5803.
34. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, et al.(2004) Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23: 1000-1004.
35. Garcia-Cao M, O'Sullivan R, Peters AH, Jenuwein T, Blasco MA, (2004) Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat Genet 36: 94-99.
36. Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, et al.(2008) Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS ONE 3: e3695.